Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619879 · ClinicalTrials.gov registry record
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
A clinical trial, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Completed
- Registry status
- 81
- Enrollment target
NCT00619879 is a clinical trial that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 81 participants.
The verdict
NCT00619879 has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.
Interventions
- DRUG Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients
- DRUG Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
- OTHER Hematopoietic Progenitor Cell Transplantation (HPCT)
- RADIATION CNS radiation treatment for ALL with prior CNS disease patients
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2007-03-26 |
| Est. Completion | 2019-02-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619879
The ClinicalTrials.gov registry entry for NCT00619879 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients is the first listed.
NCT00619879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00619879 about?
NCT00619879 is a clinical study titled "Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies". The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.
What is the current status of trial NCT00619879?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2007-03-26. Estimated completion is 2019-02-07.
What interventions are being tested in trial NCT00619879?
The interventions under investigation include: Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients (DRUG), Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies (DRUG), Hematopoietic Progenitor Cell Transplantation (HPCT) (OTHER), CNS radiation treatment for ALL with prior CNS disease patients (RADIATION).
Who is sponsoring clinical trial NCT00619879?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.